title: Expression of tenascin in human cervical cancer--association of tenascin expression with clinicopathological parameters.
abstract: OBJECTIVE
  Tenascin is an extracellular matrix glycoprotein, relevant for embryonal and fetal development, which is reexpressed in the stroma of benign and malignant tumors. Little is known about the molecular interaction of tenascin during neoplastic transformation and tumor progression in cervical cancer.
  
  
  METHODS
  We studied the expression of tenascin in normal tissue of the cervix uteri, cervical carcinoma in situ, and invasive cervical carcinoma in paraffin sections by immunohistochemistry using a monoclonal antibody. Tenascin immunoreactivity was compared with various prognostic parameters.
  
  
  RESULTS
  In normal cervical tissue (n = 5) and in cervical carcinoma in situ (n = 10) only vessel walls showed a weak tenascin cross-reactivity, whereas tenascin was not expressed in the epithelial layer or the underlying connective tissue. In invasive cervical carcinoma (n = 89) tenascin expression was markedly increased. In 84% (n = 75) of the cases examined a strong tenascin immunoreactivity was noted around and within the tumor cell nests. Sixteen percent (n = 14) of infiltrating cervical carcinomas showed no tenascin immunoreactivity. A definite correlation was found between weak or no tenascin expression and slight desmoplastic mesenchymal reactivity (n = 42/91%, P < 0.001), lymphatic space invasion (n = 54/81%, P < 0.001), and lymph node metastases (n = 30/77%, P < 0.05). Tenascin-positive patients had a significantly better prognosis than tenascin-negative patients (mean survival time of 56.5 +/- 4.1 months versus 31.9 +/- 5.6 months, P < 0.05).
  
  
  CONCLUSIONS
  Based on these findings we discuss that the appearance of tenascin is an indicator of an adequate biological defense in cervical cancer patients. The tenascin staining may therefore be useful for detecting a subgroup of invasive cancer patients missing tenascin reactivity with alterations of stromal defense and a poorer prognosis.
authors.affiliation: Department of Obstetrics and Gynecology, University of Mainz, Mainz, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Pilch
authors.forename: U
authors.initials: U
authors.lastname: Schäffer
authors.forename: K
authors.initials: K
authors.lastname: Schlenger
authors.forename: A
authors.initials: A
authors.lastname: Lautz
authors.forename: B
authors.initials: B
authors.lastname: Tanner
authors.forename: M
authors.initials: M
authors.lastname: Höckel
authors.forename: P G
authors.initials: PG
authors.lastname: Knapstein
mesh_terms: D002278:Carcinoma in Situ / Q000378:metabolism* / Q000401:mortality*; D018450:Disease Progression; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D019063:Tenascin / Q000096:biosynthesis*; D002583:Uterine Cervical Neoplasms / Q000378:metabolism* / Q000401:mortality*
chemical_list: D019063:Tenascin